We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Inspiration Healthcare Group Plc | LSE:IHC | London | Ordinary Share | GB00BXDZL105 | ORD 10P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 31.50 | 31.00 | 32.00 | 31.50 | 31.50 | 31.50 | 13,008 | 08:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Home Health Care Services | 41.23M | 272k | 0.0040 | 78.75 | 21.48M |
From Apr 2023 to Apr 2024
TIDMIHC
RNS Number : 1893Y
Inspiration Healthcare Group PLC
03 May 2023
3 May 2023
Inspiration Healthcare Group plc
("Inspiration Healthcare", the "Group" or the "Company")
Preliminary Unaudited Results for the year ended 31 January 2023
A Year of Significant Investment For Long Term Growth
Inspiration Healthcare Group plc (AIM: IHC), the global medical technology company, pioneering best-in-class, specialist neonatal intensive care medical devices, announces its preliminary results for the twelve months ended 31 January 2023 ("FY2023").
2023 Highlights
-- Resilient revenues marginally ahead in a year of unprecedented global macro-economic uncertainty
-- Domestic sales growth of 13% -- Branded Products sales growth of 8% -- Major investment in new state of the art Manufacturing and Technology Centre
o very low carbon footprint
o enhanced customer education facilities
o increased capacity and capability
o rationalisation of Group property portfolio underway
-- Medical Device Regulation (EU) - Technical Files all submitted -- Increasing inventory to secure long term supply chain and meet customer satisfaction levels -- Project Wave study recruitment complete - analysis underway -- Progressed USA regulatory submissions
-- Expanded acute care portfolio with launch of additional distributed products in the UK and Ireland
2023 Financial Highlights
-- Group revenue of GBP41.2m (FY2022: GBP41.1m)
Adjusted EBITDA(1) of GBP4.0m (FY2022: GBP6.4m) reflecting a gross margin reduction (44% vs 50%) due to product mix in different territories
-- Net cash(2) GBP(3.8)m (FY2022: GBP9.3m) due to:
o investment in the Company's Manufacturing and Technology Centre;
o increased inventories to ensure continuity of supply chain and customer service level;
o higher debtors driven by strong Q4 revenues; and
o non-recurring items particularly aborted acquisition costs
-- Invoice discounting facility put in place in December 2022 - Facility up to GBP5m. Total available borrowing facilities, including existing GBP5m RCF, now GBP10m
-- Proposed final dividend maintained at 0.41p per share (FY2022: 0.41p)
(1) Earnings before interest, tax, depreciation, amortisation, impairment, share-based payments and non-recurring items
(2) Cash and cash equivalents, less revolving credit facility and invoice finance borrowings
Post year-end
-- Cash generative in Q1 FY2024 -- Extension to the SLE6000 ventilator range
Neil Campbell, Chief Executive Officer of Inspiration Healthcare Group plc, said: "Last year we showed resilience and the ability to adapt our plans to maintain revenues despite geo-political and macro-economic uncertainty. Although the growth in the business was not as strong as we had hoped, the investments made during the year, coupled with increasing revenues in Q4 FY2023 and subsequent cash generation in Q1 FY2024, means the Company is well positioned to return to growth within this year. On behalf of the Board and all the team, I would like to thank our shareholders for their continued support and we look forward to an exciting year ahead."
Enquiries:
Inspiration Healthcare Group plc Tel: +44 (0)330 175 0000 Neil Campbell, Chief Executive Officer Paul Bergin, Interim Chief Financial Officer Cenkos Securities plc (Nominated Tel: +44 (0)207 397 8900 Adviser & Broker) Stephen Keys, Katy Birkin, Dan Hodkinson Walbrook PR Ltd (Media and Investor Tel: +44 (0)20 7933 8780 or inspirationhealthcare@walbrookpr.com Relations) Anna Dunphy Mob: +44 (0) 7876 741 001 Stephanie Cuthbert Mob: +44 (0) 7796 794 663
Chairman's Report
This year I am reporting on a year of significant investment and internal achievements. Despite challenging market conditions that arose during the year we continued to make progress to position the Company for long-term sustainable growth.
The conflict in Ukraine and, consequently, inflation and shifting confidence put significant pressures on healthcare budgets and spending. Coupled with this, we have to also acknowledge that in China, the largest export market for the Group's products in the previous year, the pandemic was still problematic. The authorities determined that the best way to deal with this terrible disease was further lockdowns, making trade with China more difficult than in previous years. This also disrupted supply chains for both logistics and materials sourced.
The Group delivered revenues that were marginally ahead of FY2022 at GBP41.2m (FY2022: GBP41.1m), which reflected growth outside of China and Russia, traditionally important markets for the Group. When I look back and see the issues that were thrown at us, (along with many other companies), I am proud that we achieved much and invested in the business to ensure that we are in better shape now than we were a year ago.
EBITDA, before non-recurring items, was lower than the previous year at GBP4.0m (FY2022: GBP6.4m) primarily because of sales mix and its effect on gross margin. Notably we sold more Infusion Therapies Distributed Products into the UK market and less Branded ventilators due to global market uncertainties. This switch was a direct result of the external environment mentioned above.
There was a GBP13.1m cash outflow in the year resulting in a closing net cash position of GBP(3.8)m, driven by investment in the new Manufacturing and Technology Centre in Croydon, an increased inventory level to ensure continuity of supply and customer service levels and increased debtors from strong fourth quarter revenues. Higher than planned spend at the Manufacturing and Technology Centre was due to high construction cost inflation, an earlier than expected payment and specification changes. These specification changes will however deliver long-term cost savings. We delivered a positive cash flow position in Q1 FY2024, in line with our plan.
Our new Manufacturing and Technology Centre has enabled us to close our Crawley office at the end of January 2023, and in April 2023 we informed the staff affected that we will be closing our Leicestershire facility. From these closures, we will see additional operational efficiencies. We have identified further initiatives within the business, that will improve our cash-based operating expenses going forward.
It is important to emphasise that, although we are focused strategically on the neonatal intensive care sector, we have always had a broad portfolio which provides resilience to the business. This was demonstrated during the year when slowdown in international sales was offset by increased revenues in our Domestic market.
Investing for Growth
Our most notable investment is in our new Manufacturing and Technology Centre in Croydon, which was the home of SLE Ltd, a company we acquired in 2020. Maintaining the highly skilled workforce was paramount and it was important to find a site suitable for high tech manufacturing, along with the facilities we need as a fully integrated company (including research and development and technology support). Now with approximately 4,200 sq metres (50% more space than the previous Croydon site), the state-of-the-art design allows for more efficient warehousing and laboratories for product development and testing, along with creating a modern working environment for our employees. I am pleased to say that we completed the move in the first half of the year with no accidents and with only one day of lost production. The site is now fully operational and helped us deliver a record month at the end of our financial year.
The Manufacturing and Technology Centre has been developed with the future in mind. We have incorporated a number of energy-saving initiatives; solar panels on the roof help provide hot water and power to our air source heat pumps for heating the buildings, roof lights have been maintained which allow us to use low energy lighting and in the summer months turn off lighting altogether. With the addition of trees and plants that produce no resins or pollens and do not attract aphids, carbon dioxide is naturally processed within the building, reducing the number of air changes needed and hence reducing the energy required for heating and cooling. Numerous other initiatives have been incorporated and we feel that this is a true demonstration of what can be achieved by smaller British manufacturing companies.
Our employees are at the heart of the company and in addition, we have implemented sit/stand desks throughout, modern work benches for manufacturing and technology support, electric charging points for electric cars, open plan break out areas for informal meetings and, of course a safe environment that would minimise disruption in the event of another Covid-19 outbreak, with ultra-violet and HEPA-filtered air handling alongside modern communication facilities that allow for a true clear desk policy.
Ahead of New Regulatory Requirements
Around the end of 2022, the European Commission proposed, and subsequently enacted, to delay the implementation of some aspects of the new Medical Device Regulations, relieving some pressure on the Notified Bodies. The UK Government has also postponed the introduction of regulatory legislation. Our team has been worked hard, mainly in our Research and Development and regulatory groups, updating our technical documentation, writing new reports that are required by the new regulations and finally submitting all our Technical Files to our Notified Body for their review ahead of this deadline. It has been a huge amount of work and was completed before the announcement of the postponement of the deadlines. However, the sooner the files were submitted, the sooner the products would be approved to the latest regulations, and we take comfort in knowing our technical documentation is up-to-date. Bringing the companies together is quite a complex regulatory challenge, aligning quality management systems to work efficiently. This has been helped by the implementation of Trackwise Digital, our new software tool for helping our document management compliance, which has received positive feedback from our Notified Body.
Our market seems to be returning to normal with activity at our biggest trade shows returning close to pre-pandemic levels. We had a strong presence at both shows we attended enabling our international sales and marketing team to meet distributors face-to-face for the first time, in some cases, since pre-Covid. We have been rolling out a number of marketing initiatives around branding, bringing more aligned messages across the three operating companies in the Group and launched a new website that went live at the end of February 2023.
Strengthened Team
During the year we improved the management of our supply chain, with the critical appointment of Francesca Stenhouse as Head of Procurement and Supply Chain. This role is pivotal in working with our suppliers, including internal and external logistics, to drive efficiencies in our business. The year has been difficult for our suppliers and I thank them for their support during the year. Without their assistance we would not have been able to produce the products we did and, although we invested in component stock, our suppliers helped with their understanding of the situation.
Jon Ballard our Chief Financial Officer, resigned during the year. On behalf of the Board, I would like to thank Jon for his hard work over the past five years and wish him all the very best for the future. Paul Bergin joined the Company as Interim CFO and the recruitment for a new permanent CFO is expected to conclude in the Summer of this year.
Our employees have endured a tough year. I can only thank them all for their support of the company during the last 12 months and we hope that we can all enjoy a better year ahead.
Positioned for Future Growth
Although the external disruptions to supply chain and markets remain, we have been able to adapt to, and cope with, this new environment. We have introduced more resilience into our supply chain and this has helped our ability to ease our customers through these uncertain times with the robust assurance of our quality and excellence of our life saving products.
Following a strong Q4 FY2023, the year has commenced in line with our plans. While uncertainties remain, we are cautiously optimistic that we will return to our usual growth patterns.
The Group's world leading expertise, broad portfolio of best-in-class, specialist products and established customer relationships enables us to address the critical needs of the neonatal intensive care market and help save lives and improve outcomes of premature and sick babies around the world. We have a clear growth strategy focused on maximising in-market sales, geographic and portfolio expansion and strategic M&A and we believe we are well placed to realise our long-term ambition of becoming a world leading provider of innovative medical technology.
Mark Abrahams
Chairman
3 May 2023
Going concern basis
The Group provides essential equipment to the NHS, to private healthcare providers and to distributors who provide the equipment to other healthcare systems internationally. With a focus on neonatal intensive care the use of the Group's products is not something that can be reduced by election or choice.
Although the Group has no information to suggest such a scenario might occur, it has modelled a significant downside scenario based on its main risks, including a significant downturn in forecast revenue of 15%. If such a scenario occurred, the Group would implement procedures to reduce overheads and if necessary, utilise the remaining undrawn Invoice Discounting Facility and Revolving Credit Facility (due for renewal June 2024).
As at 31 March 2023 net cash of the Group was (GBP2.0m), and there was cash headroom of GBP8.0m. The Group has access to borrowing facilities of up to GBP10.0m. Consequently, the Directors believe that the Group has sufficient liquidity to meet obligations as they fall due up to the end of May 2024 and consider it appropriate to prepare the financial statements on the going concern basis.
Operating and Financial Review
I am pleased to report on the Group performance for the financial year ended 31 January 2023 ("FY2023").
REVENUE
Group revenue increased 0.4% to GBP41.2m (FY2022: GBP41.1m).
Group Domestic revenue increased by 13% to GBP19.9m (FY2022: GBP17.6m) primarily driven by continuing growth in Infusion Therapies, partially offset by the planned exiting of domestic service revenue from distributed ventilation products. Macro-economic uncertainty, particularly in China, as well as the geopolitical consequence of the conflict in Ukraine, resulted in International revenue reducing overall by 9% to GBP21.3m (FY2022: GBP23.4m).
It is worth highlighting that 31% of full year revenue was generated in the fourth quarter. This expected increase in our order inflow and subsequent delivery of product was driven by increased Domestic and International capital purchases, particularly of ventilators.
BRANDED PRODUCTS
Branded Products revenue grew 8% to GBP24.4m (FY2022: GBP22.5m) driven by the fourth quarter increase in ventilator sales, referred to above, and also due to the planned exit of distributed products following the acquisition of SLE Ltd. This growth was despite the impact of global market uncertainty on certain export markets.
DISTRIBUTED PRODUCTS
Distributed Products revenue was flat year-on-year at GBP13.6m (FY2022: GBP13.6m). Continued growth in our Infusion product range was offset by the planned exit from third-party ventilator sales. These third-party ventilators are being replaced with SLE ventilators in the UK and Ireland, contributing to an increase in Branded Products.
TECHNOLOGY SUPPORT
Technology Support revenue reduced 37% to GBP2.9m (FY2022: GBP4.6m). This reduction was impacted by the planned exiting of third-party ventilators and the Tecotherm cooling device change of service arrangements related to its end of life. Group total revenue also includes GBP0.3m of freight (FY2022: GBP0.4m).
GROSS PROFIT
Gross profit of GBP18.1m was 12% lower than the prior year (FY2022: GBP20.6m). With revenue broadly flat, this reflected a gross margin reduction from 50.2% to 43.9%. This reduction was driven by the mix of products in different territories and a lower revenue from Technology Support which is at high margins.
OPERATING PROFIT
The Group reported Adjusted Operating Profit (before non-recurring items) of GBP1.6m (FY2022: GBP4.3m).
Administrative expenses were broadly flat year-on-year at GBP16.5m (FY2022: GBP16.3m), despite the highly inflationary macro-economic environment.
There were GBP1.2m of non-recurring items in the year (FY2022: nil), comprising GBP0.5m of leased property impairment relating to the consolidation of our property portfolio following the move to the new Manufacturing and Technology Centre, GBP0.5m of aborted acquisition costs and GBP0.2m of other costs (see note 4).
This resulted in an Operating profit, post non-recurring items, of GBP0.4m (FY2022: GBP4.3m).
Adjusted EBITDA reduced to GBP4.0m (FY2022: GBP6.4m). With revenue and administrative expenses broadly flat year-on-year, this reduction was primarily driven by the mix of products in different territories. Adjusted EBITDA margin reduced from 15.6% to 9.7%.
Hot Features
Premium
2023 2022 Change
GBP'000 GBP'000 GBP'000
Operating Profit 431 4,255 (3,824)
---------------------------- -------- -------- --------
Non-recurring items 1,158 - 1,158
---------------------------- -------- -------- --------
Adjusted Operating Profit 1,589 4,255 (2,666)
---------------------------- -------- -------- --------
Depreciation 1,354 1,069 285
Amortisation of intangible
assets 931 837 94
Impairment of right of use
asset - 122 (122)
Share based payment 132 139 (7)
Adjusted EBITDA 4,006 6,422 (2,416)
---------------------------- -------- -------- --------
Taxation
The Group has recorded a tax credit of GBP196,000 (FY2022: GBP271,000).
Earnings Per Share ("EPS")
Basic EPS and diluted EPS were 0.40p per share and 0.39p per share, respectively (FY2022: 6.22p and 6.16p).
Adjusted basic and diluted EPS (before non-recurring items) were 2.99p and 2.95p, respectively (FY2022: 7.11p and 7.04p).
Cash Flow
Net cash (cash and cash equivalents less the Company's Revolving Credit Facility "RCF" and invoice financing facility) was GBP(3.8)m as at 31 January 2023 (FY2022: GBP9.3m). The GBP13.1m decrease in the year was driven by the investment in the new Manufacturing and Technology Centre in Croydon (including an earlier than expected payment), increased inventory levels to ensure continuity of supply chain and customer service level, higher debtors due to strong fourth quarter revenues and non-recurring items.
Net cash flows used in operating activities was a GBP3.5m outflow (FY2022: GBP3.6m inflow), with the decrease reflecting the increased working capital level, referred to above, as well as lower profitability.
Cash outflow on investing activities was GBP8.3m (FY2022: GBP4.0m) of which GBP2.0m related to capital development expenditure and the majority of the balance to investment in the new Manufacturing and Technology Centre. There was also GBP1.3m of financing outflows.
The Group has a GBP5m RCF in place and during December 2022 entered into an invoice discounting facility of up to GBP5m. As at 31 January 2023, GBP4.0m of the RCF and GBP2.1m of the invoice discounting facility were utilised. Total headroom as at 31 January was GBP6.2m.
Net Assets
The value of non-current assets as at 31 January 2023 totalled GBP30.8m (FY2022: GBP25.1m). The net GBP5.7m year-on-year increase mostly relates to investment in the new Manufacturing and Technology Centre.
Inventory increased to GBP9.9m (FY2022: GBP6.4m) which was impacted by the need to secure components to ensure continuity of supply chain. Trade and other receivables increased by GBP2.6m to GBP11.9m (FY2022: GBP9.3m), reflecting a planned strong fourth quarter order and revenue level. Trade and other payables decreased by GBP0.8m to GBP5.8m (FY2022: GBP6.6m).
Net Assets remained flat at GBP35.5m as at 31 January 2023.
Dividends
The interim dividend of 0.205p per share (FY2022: 0.205p) was paid on 28 December 2022. The Board is recommending a final dividend of 0.41p per share (FY2022: 0.41p) to make a total dividend for the year of 0.615p per share (FY2021: 0.615p). If approved by shareholders at the AGM, the final dividend will be paid on 28 July 2023 to shareholders on the register on 30 June 2023.
Review of Business and Future Developments
On a Group basis the business review and future prospects are set out in the Chairman's Report above.
Share Price During the Year
The range of market prices during the year from 1 February 2022 to 31 January 2023 was 52p to 113.5p and the mid-market price of the Company's ordinary shares at 31 January 2023 was 52p.
Neil Campbell
Chief Executive Officer
3 May 2023
Consolidated Income Statement
for the year ended 31 January 2023
2023 2023 2023 2022
Non-recurring
items Total
Adjusted GBP'000 Total Restated
Note GBP'000 GBP'000 GBP'000
Revenue 2 41,233 - 41,233 41,050
Cost of sales (23,140) (23,140) (20,458)
-
------------------------ ---- ---------- ------------- -------- ---------
Gross profit 18,093 - 18,093 20,592
Administrative expenses 4 (16,504) (1,158) (17,662) (16,337)
Operating profit 1,589 (1,158) 431 4,255
Finance income 40 - 40 9
Finance expense (395) - (395) (301)
Profit before tax 1,234 (1,158) 76 3,963
Income tax 3 196 - 196 271
Profit for the year
attributable to
owners of the parent
company 1,430 (1,158) 272 4,234
Earnings per share,
attributable to owners
of the
parent company
Basic expressed in
pence per share 5 2.99p 0.40p 6.22p
Diluted expressed
in pence per share 5 2.95p 0.39p 6.16p
A Prior Year Adjustment has been made in relation to Deferred Tax and consequently, an adjustment to Income Tax has been made to the Consolidated Income Statement for the year ended 31 January 2022. Please see Note 12 for further detail.
Consolidated Statement of Comprehensive Income
for the year ended 31 January 2023
2023 2023 2023 2022
Non-recurring
Adjusted items Total Restated
GBP'000 GBP'000 GBP'000 GBP'000
Profit for the year 1,430 (1,158) 272 4,234
Other comprehensive income
Items that may be reclassified
to profit or loss
Cash flow hedges - - - 9
Total other comprehensive
income for the year - - - 9
Total comprehensive income
for the year 1,430 (1,158) 272 4,243
Consolidated Statement of Financial Position
as at 31 January 2023
(Registered Number:
03587944)
2023 Restated
2022
Note GBP'000 GBP'000
Assets
Non-current assets
Intangible assets 7 17,004 15,825
Property, plant and
equipment 8 7,497 1,798
Right of use assets 5,970 7,383
Deferred tax asset 11 324 87
---------------------------- ---- -------- --------
30,795 25,093
Current assets
Inventories 9,935 6,449
Trade and other receivables 11,888 9,313
Cash and cash equivalents 9 2,276 9,253
---------------------------- ---- -------- --------
24,099 25,015
Total assets 54,894 50,108
Liabilities
Current liabilities
Trade and other payables (5,812) (6,552)
Lease liabilities (822) (647)
Borrowings 10 (2,079) -
Contract liabilities (531) (524)
(9,244) (7,723)
Non-current liabilities
Lease liabilities (6,176) (6,896)
Borrowings 10 (4,000) -
(10,176) (6,896)
Total liabilities (19,420) (14,619)
Net assets 35,474 35,489
Shareholders' equity
Called up share capital 6,813 6,812
Share premium account 18,842 18,838
Reverse acquisition
reserve (16,164) (16,164)
Share based payment
reserve 405 278
Retained earnings 25,578 25,725
---------------------------- ---- -------- --------
Total equity 35,474 35,489
A Prior Year Adjustment has been made in relation to Deferred Tax and consequently, adjustments to Goodwill and Deferred Tax have been made in the Consolidated Statement of Financial Position as at 31 January 2022. Please see Note 12 for further detail.
Consolidated Statement of Changes in
Shareholders' Equity
Share
Issued Share Reverse based
share premium acquisition payment Other Retained
capital account reserve reserve Reserves earnings Total
GBP'000 GBP'000 GBP'000 GBP'000 GBP'000 GBP'000 GBP'000
At 1 February
2021 (Restated) 6,812 18,838 (16,164) 139 (9) 21,903 31,519
Profit for the
year (Restated) - - - - - 4,234 4,234
Cash flow hedges:
Income recognised
on hedging
instruments - - - - 9 - 9
Total comprehensive
income for the
year - - - - 9 4,234 4,243
Transactions
with owners in
their capacity
as owners
Dividends - - - - - (412) (412)
Employee share
scheme expense - - - 139 - - 139
------------------- ------- ------- ----------- ------- -------- -------- -------
Total transactions
with owners - - - 139 - (412) (273)
At 31 January
2022 (Restated) 6,812 18,838 (16,164) 278 - 25,725 35,489
Profit for the
year - - - - - 272 272
Total comprehensive
income for the
year - - - - - 272 272
Transactions
with owners in
their capacity
as owners
Issue of ordinary
shares, net of
transaction costs
and tax 1 4 - (5) - - -
Dividends - - - - - (419) (419)
Employee share
scheme expense - - - 132 - - 132
Total transactions
with owners 1 4 - 127 - (419) (287) At 31 January 2023 6,813 18,842 (16,164) 405 - 25,578 35,474
Consolidated Cash Flow Statement
for the year ended 31 January 2023
Restated
2023 2022
Note GBP'000 GBP'000
Cash flows from operating activities
Profit for the year 272 4,234
Adjustments for:
Depreciation and amortisation 2,285 1,906
Remeasurement of leases (25) (46)
Impairment of right of use assets 446 122
Employee share scheme expense 132 139
(Profit)/Loss on disposal of
tangible assets (26) 192
Loss on disposal of intangible
assets 6 133
Finance income (40) (9)
Finance expense 395 301
Income tax 3 (196) (271)
---------------------------------------- ---- ------- --------
3,249 6,701
(Increase)/decrease in inventories (3,486) 1,741
Increase in trade and other receivables (2,501) (4,037)
Decrease in trade and other payables (740) (266)
Increase/(Decrease) in contract
liabilities 7 (9)
Cash flows (used in)/generated
from operations (3,471) 4,130
Taxation paid 3 - (554)
Net cash (used in)/generated
from operating activities (3,471) 3,576
Cash flows from investing activities
Bank interest received 5 1
Interest received on leases 35 8
Purchase of property, plant and
equipment (6,226) (1,425)
Purchase of intangible assets 7 (140) (338)
Capitalised development costs 7 (1,976) (2,208)
Net cash used in investing activities (8,302) (3,962)
Cash flows from financing activities
Principal elements of lease payments (697) (382)
Principle elements of lease receipts 217 74
Interest paid on lease liabilities (300) (244)
Interest paid on loans and borrowings (84) (50)
Dividends paid to the holders
of the parent (419) (412)
Proceeds from loans and borrowings 10 6,079 -
Net cash generated from/(used
in) financing activities 4,796 (1,014)
Net decrease in cash and cash
equivalents (6,977) (1,400)
Cash and cash equivalents at
the beginning of the year 9,253 10,653
Cash and cash equivalents at
the end of the year 2,276 9,253
Notes forming part of the Consolidated Financial Statements
1 Accounting Policies
Inspiration Healthcare Group plc ("Company") is a public limited company incorporated in England and Wales and domiciled in England. The Company's registered address is Unit 2, Satellite Business Village, Crawley, West Sussex, RH10 9NE and the registered company number is 03587944. The Company's ordinary shares are traded on the AIM Market of the London Stock Exchange plc.
The principal activities of Inspiration Healthcare Group plc and its subsidiaries (together, the "Group") continue to be the sale, service and support of critical care equipment to the medical sector including hospitals.
Basis of preparation
The principal accounting policies adopted in the preparation of these financial statements are set out below. These policies have been consistently applied unless otherwise stated.
The individual financial statements of each entity in the Group are presented in the currency of the primary economic environment in which it operates (the functional currency). The Group Financial Statements are presented in pounds sterling, which is the presentation currency of the Group.
Alternative financial measures
In the reporting of its financial performance, the Group uses certain measures that are not defined under IFRS, the Generally Accepted Accounting Principles (GAAP) under which the Group reports. The Directors believe that these non-GAAP measures assist with the understanding of the performance of the business. These non-GAAP measures are not a substitute for, or superior to, any IFRS measures of performance but they have been included as the Directors consider them to be an important means of comparing performance year-on-year and they include key measures used within the business for assessing performance.
The Group refers to the following alternative financial measures, please refer to the Operating and Financial Review for further information.
-- Adjusted EBITDA -- Adjusted Operating Profit -- Adjusted EPS 2 Revenue
The Group derives revenue from the transfer of goods and services over time and at a point in time in the following geographical split:
2023 2022
GBP'000 GBP'000
Domestic
* UK 19,340 17,078
* Ireland 547 545
International
* Europe 5,315 5,955
* Asia Pacific 9,458 10,230
* Middle East & Africa 5,386 5,456
* Americas 1,187 1,786
Total 41,233 41,050
Significant categories
of revenue
2023 2022
GBP'000 GBP'000
Revenue recognised at
a Point in Time
* Branded Products 24,360 22,524
* Distributor Products 13,624 13,606
* Technology Support * 261 304
* Freight 360 356
Revenue recognised Over
Time
* Technology Support 2,628 4,260
Total 41,233 41,050
* Technology Support revenue recognised at a point in time relates to the rental of our AlphaCore(5) patient warming equipment.
3 Income tax
(a) Analysis of tax charge for the
year
2023 2022
GBP'000 GBP'000
Domestic current year tax *
UK corporation tax
Current year 14 -
Prior year adjustment 28 56
Total current tax expense 42 56
Deferred tax
Origination and reversal of temporary
timing differences (306) (311)
Prior year adjustment 68 (16)
Total deferred tax (238) (327)
Tax expense on profit on ordinary
activities (196) (271)
* All tax in both FY2023 and FY2022 arose in the UK.
(b) Analysis of current corporation
tax assets
2023 2022
GBP'000 GBP'000
Net liability at 1 February 185 (313)
Tax payments
Final payments relating to prior year - 554
Total tax payments made during the
year - 554
Current year UK corporation tax charge (14) -
Prior year adjustment (28) (56)
Net asset at 31 January 143 185
(c) Factors affecting tax charge for the year
The tax assessed for the year is lower (2022: lower) than the standard rate of corporation tax in the UK 19.00% (2022: 19.00%) as explained below:
Effective Tax
Rate
2022 2022
2023 Restated 2023 Restated
GBP'000 GBP'000 %%
Profit on ordinary activities
before taxation 76 3,963
------------------------------ ------- --------- --------- ---------
Tax using the effective
UK corporation tax rate
of 19.00% (2022: 19.00%) 14 753 19.0 19.0
Effects of:
Non-deductible expenses 188 56 247.3 1.4
Additional deduction for
research and development (314) (497) (413.7) (12.5)
Fixed asset differences 44 49 58.3 1.2
Other permanent differences - 12 - 0.3
Adjustment in respect of
prior periods 96 40 126.5 1.0
Amendments to deferred
tax and timing (224) (684) (295.2) (17.3)
------------------------------ ------- --------- --------- ---------
Total tax expense (196) (271)
------------------------------ ------- --------- --------- ---------
Effective tax rate (257.8) (6.9)
------------------------------ ------- --------- --------- ---------
The effective tax rate for FY2023 is lower than FY2022. This decrease is largely due to the recognition of previously unrecognised losses. The non-deductible expenses largely relate to aborted acquisition costs incurred in the year.
Budget 2021 announced that the UK corporation tax rate was to increase from 19% to 25% with effect from 1 April 2023. A small profits rate of 19% applies for taxable profits of GBP50,000 or less and a tapered rate will apply to companies with taxable profits between GBP50,001 and GBP249,999. This provision was substantively enacted on 24 May 2021 and the deferred tax balances have been calculated at 25%.
(d) Factors that may affect future tax charges
The Group has gross unrecognised losses estimated at GBP6,019,271 (FY2022: GBP6,019,271) which were transferred to the Group due to the reverse acquisition of Inditherm. Brought forward losses transferred to the Group due to the reverse acquisition are potentially available for relief against future trading profits generated from the same trade. See note 11 Deferred Tax, for more information.
4 Non-recurring Items
During the year, the Group recognised the
following non-recurring items:
2023
GBP'000
Impairments of leased properties 446
Aborted acquisition costs 467
Other 245
-----------
Total Non-recurring items 1,158
-----------
Impairment of leased properties:
Following the move to our new Manufacturing and Technology Centre,
the Group took the decision to consolidate its property portfolio
and as a result, there was an impairment of our right of use assets
of GBP446,000, relating to our Crawley and former Croydon properties.
Aborted acquisition costs:
GBP467,000 were financial and tax due diligence work and consultancy
fees related to an aborted acquisition.
Other
GBP105,000 relates to project consultancy costs incurred in the
year. GBP140,000 were legal fees relating to a contract dispute.
5 Earnings per ordinary share
Basic earnings per share for the year is calculated by dividing the profit attributable to ordinary shareholders for the year after tax by the weighted average number of shares in issue.
Diluted earnings per share is calculated by adjusting the weighted average number of ordinary shares in issue to assume conversion of all potential dilutive ordinary shares.
FY2022 earnings per share have been restated as a result of the Prior Year adjustment relating to deferred tax, please see Note 12 for further detail.
2022
2023 Restated
GBP'000 GBP'000
Profit
Profit attributable to equity holders
of the company 272 4,234
Add back non-recurring items 1,158 -
Add back amortisation of intangible
assets acquired through business
combinations 605 605
Numerator for adjusted earnings
per share calculation 2,035 4,839
The weighted average number of shares in issue and the diluted weighted average number of shares in issue were as follows:
2023 2022
Shares
Number of ordinary shares in issue
at the beginning of the year 68,127,447 68,121,447
Weighted average number of shares issued
during the year 5,771 -
----------------------------------------- ---------- ----------
Weighted average number of ordinary
shares in issue during the year 68,133,218 68,121,447
for the purposes of basic earnings
per share
Dilutive effect of potential ordinary
shares:
Weighted average number of share options 691,392 672,175
Diluted weighted average number of
shares in issue during the year
for the purposes of diluted earnings
per share 68,824,610 68,793,622
The basic and diluted earnings per share for the year are as follows:
Basic Diluted Basic Diluted
2022 2022
2023 2023 Restated Restated
pence pence pence pence
Earnings per share 0.40 0.39 6.22 6.16
--------------------------- ----- ------- --------- ---------
Adjust for:
Non recurring items 1.70 1.68 - -
Add back amortisation
of intangible assets
acquired through business
combinations 0.89 0.88 0.89 0.88
Adjusted earnings per
share 2.99 2.95 7.11 7.04
An adjusted basic earnings per share and an adjusted diluted earnings per share have also been calculated as in the opinion of the Directors this will allow shareholders to gain a clearer understanding of the trading performance of the Group.
6 Dividends
The interim dividend for the year ended 31 January 2023 of 0.205p per share (2021: 0.2p per share) was paid on 28 December 2022. The proposed final dividend of 0.41p per share (2022: 0.4p per share) is subject to approval by shareholders at the AGM and has not been recognised as a liability as at 31 January 2023. If approved, the final dividend will be paid on 28 July 2023 to shareholders on the register on 30 June 2023.
7 Intangible assets
Intangible
assets Development Intellectual Software
Goodwill acquired costs property costs Total
GBP'000 GBP'000 GBP'000 GBP'000 GBP'000 GBP'000
Cost
At 1 February
2021 (Restated) 7,610 5,528 2,035 276 485 15,934
Capitalised in
the year - - 2,208 - 338 2,546
Disposals - - (116) - (67) (183)
At 1 February
2022 7,610 5,528 4,127 276 756 18,297
Capitalised in
the year - - 1,976 - 140 2,116
Disposals - - (6) - - (6)
At 31 January
2023 7,610 5,528 6,097 276 896 20,407
Accumulated
Amortisation
At 1 February
2021 - 423 625 276 361 1,685
Charge in the
year - 605 155 - 77 837
Disposal - - - - (50) (50)
----------------- -------- ---------- ----------- ------------ -------- -------
At 1 February
2022 - 1,028 780 276 388 2,472
Charge in the
year - 605 157 - 169 931
At 31 January
2023 - 1,633 937 276 557 3,403
Net book value
At 31 January
2023 7,610 3,895 5,160 - 339 17,004
At 31 January
2022 (Restated) 7,610 4,500 3,347 - 368 15,825
The Group tests goodwill for impairment on an annual basis, or more frequently if there are indications that the goodwill may be impaired. The recoverable amounts of the cash-generating unit are determined from value in use calculations. The key assumptions for the value in use calculations are the discount and growth rates used for future cash flows and the anticipated future changes in revenue and costs. The assumptions used reflect the past experience of management and future expectations.
The forecasts covering a five-year period are based on the detailed budget for the year ended 31 January 2024 approved by management. The cashflows beyond the budget are extrapolated for a further four-year period based on future expectations. This forecast is then extrapolated to perpetuity using a 2% (2022: 2%) growth rate.
Annual growth rates for revenues for the five-year forecast period have been included between 10% and 15% year-on-year and costs between 5% and 10% year-on-year. A post-tax discount rate of 13% (2022: 13%) has been used in these calculations. The discount rate uses weighted average cost of capital which is reflective of a medical device Company operating both domestically and internationally. A discount rate of 19% (2022: 31%) would need to be applied for there to be zero headroom.
Sensitivity analyses have been performed on the carrying value of all remaining goodwill using post-tax discount rates up to 13%. Revenue growth would need to reduce by 4.1% year-on-year with no change in cost growth assumptions for there to be zero headroom.
8 Property, Plant and Equipment
Plant,
machinery,
Leasehold Fixtures office Motor
improvements and fittings equipment vehicles Total
GBP'000 GBP'000 GBP'000 GBP'000 GBP'000
Cost
At 1 February
2021 467 121 1,516 58 2,162
Additions in
the year 899 2 525 - 1,426
Disposals in
the year (220) (17) (154) - (391)
At 1 February
2022 1,146 106 1,887 58 3,197
-------------- ---------------------------- ------------------------- ----------- ----------------------- --------
Additions in
the year 5,894 6 326 - 6,226
Disposals in
the year - - (6) - (6)
At 31 January
2023 7,040 112 2,207 58 9,417
-------------- ---------------------------- ------------------------- ----------- ----------------------- --------
Accumulated
Depreciation
At 1 February
2021 114 61 1,061 7 1,243
Charge in the
year 73 24 249 17 363
Disposals in
the year (58) (17) (132) - (207)
At 1 February
2022 129 68 1,178 24 1,399
-------------- ---------------------------- ------------------------- ----------- ----------------------- --------
Charge in the
year 241 8 257 17 523
Disposals in
the year - - (2) - (2)
At 31 January
2023 370 76 1,433 41 1,920
-------------- ---------------------------- ------------------------- ----------- ----------------------- --------
Net book
value
At 31 January
2023 6,670 36 774 17 7,497
--------
At 31 January
2022 1,017 38 709 34 1,798
-------------- ---------------------------- ------------------------- ----------- ----------------------- --------
Depreciation charged for the financial year is split between cost of sales GBP60,000 (2022: GBP19,000) and administrative expense GBP463,000 (2022: GBP344,000) in the Consolidated Income Statement.
9 Cash and cash equivalents
Cash and cash equivalents comprise solely of cash at bank available on demand.
The Group currently use four banks; Royal Bank of Scotland plc, HSBC Bank plc, Bank of Scotland plc and National Westminster Bank plc. Moody's give long-term ratings of A1 for all four banks as at 31 January 2023.
10 Borrowings
2023 2022
Note GBP'000 GBP'000
---------------------------------- ----- -------- --------
Revolving Credit Facility ("RCF") 4,000 -
Invoice Financing 2,079 -
6,079 -
-------- --------
GBP4m has been presented as a non-current liability in the Statement of Financial Position as at 31 January 2023 and GBP2.1m has been presented as a current liability.
Revolving Credit Facility
The Group has a GBP5m RCF facility in place, which expires in 2024 with the option to extend and attracts a 2.5% margin above SONIA. During the year, the Group utilised GBP4m of the RCF facility. Banking covenants of EBITDA / finance charges and net debt / EBITDA are in place and are tested quarterly. All covenants have been complied with during the year ended 31 January 2023.
Drawdowns can be made on a 1, 2 or 3 month basis which can be rolled as required until the facility expires.
The movement in the RCF facility during the year was as follows:
.
GBP'000
--------
At 1 February 2022 -
Proceeds from drawdown of loans 4,000
Interest payable 84
Interest paid (84)
At 31 January 2023 4,000
--------
Invoice Financing Facility
During the year, the Group entered into an invoice financing facility to borrow cash against notifiable trade receivables. The arrangement with the bank is such that the customers remit cash directly with the bank and invoices are settled against the facility directly. The Group continues to bear the credit risk relating to any defaulting customers and therefore the related trade receivables continue to be recognised on the Group's Statement of Financial Position.
11 Deferred tax
The following are the major deferred tax liabilities and assets recognised by the Group and movements thereon during the current and prior reporting year.
The Group has made a prior year adjustment in respect of the FY2021 deferred tax asset arising on acquisition of SLE Limited. This note has been restated accordingly. Please see Note 12 for further detail of the prior year adjustment.
Note that the effective future tax rate is 25% (2022: 25%).
2023 2022
Restated
GBP'000 GBP'000
------------------------------------------------- -------- ------------
Asset at beginning of year 2,012 900
Credit to the Income Statement for
the year 351 1,112
Asset at end of year 2,363 2,012
------------------------------------------------- -------- ------------
2023 2022
GBP'000 GBP'000
------------------------------------------------- -------- ------------
Liability at beginning of year (1,925) (1,141)
Charge to the Income Statement for
the year (114) (784)
Liability at end of year (2,039) (1,925)
------------------------------------------------- -------- ------------
The elements of deferred taxation
provided for are as follows:
Restated
2023 2022
GBP'000 GBP'000
------------------------------------------------- -------- ------------
Unused tax losses relating to SLE 1,959 1,661
Unused tax losses relating to Inditherm 331 351
Short term timing differences 73 -
Deferred tax asset 2,363 2,012
------------------------------------------------- -------- ------------
2023 2022
GBP'000 GBP'000
------------------------------------------------- -------- ------------
Accelerated capital allowances (186) (140)
Intangible assets (879) (751)
Intangibles arising on business
combinations (974) (1,125)
Short term timing differences - 91
Deferred tax liability (2,039) (1,925)
------------------------------------------------- -------- ------------
Presentation on the Consolidated Statement of Financial Position
2023 2022
Deferred tax asset 324 87
--------------------- ----- -----
At the year end date the Group had gross unused losses of GBP15,248,186 (2022: GBP13,988,205) potentially available to offset against future profits. Unused trading losses of GBP7,905,283 (2022: GBP6,645,302) arose in SLE Limited prior to the acquisition by Inspiration Healthcare Group plc on 7 July 2020 and brought forward losses transferred to the Group due to the reverse acquisition of Inditherm plc amount to GBP7,342,903 (2022: GBP7,342,903). The Group has received advice that these losses can be carried forward and utilised against future taxable profits of the same business from which they were generated. A streaming methodology has been devised to estimate profits from the business relating to Inditherm plc. This has been projected forwards and it is estimated that taxable profits will be generated in the future and consequently, a deferred tax asset has been recognised in respect of these losses. A deferred tax asset has also been recognised in respect of the brought forward losses transferred to the Group following the acquisition of SLE Limited. A prior year adjustment has been made to recognise a deferred tax asset to the extent of the deferred tax liability relating to the intangibles recognised on the acquisition of SLE Limited.
The amounts of deferred tax not
recognised are as follows:
2023 2022
GBP'000 GBP'000
Unused tax losses 1,505 1,485
Budget 2021 announced that the UK corporation tax rate was to increase from 19% to 25% with effect from 1 April 2023. A small profits rate of 19% applies for taxable profits of GBP50,000 or less and a tapered rate will apply to companies with taxable profits between GBP50,001 and GBP249,999. This provision was substantively enacted on 24 May 2021 and the deferred tax balances have been calculated at 25%.
12 Prior Year Adjustment
A Prior Year Adjustment has been made in respect of the Group's deferred tax asset. In FY2021, the Group recognised a deferred tax liability relating to taxable temporary differences that arose from the recognition of intangibles on the acquisition of SLE Limited in July 2020. At the time of the acquisition, a deferred tax asset was not recognised. However, accounting standards require a deferred tax asset to be recognised to the extent of the existing deferred tax liability and therefore a deferred tax asset should have been recognised in FY2021. This has been corrected by restating each of the affected financial statement line items for prior periods. The following tables summarise the impacts on the Group's Consolidated Financial Statements.
Consolidated Statement of Financial Position
Impact of correction of error
--------------------------------------------
As previously
31 January 2022 reported Adjustments As restated
GBP'000 GBP'000 GBP'000
Intangibles 16,782 (957) 15,825
Deferred Tax Asset 470 (383) 87
Other 34,197 (1) 34,196
Total Assets 51,449 (1,341) 50,108
------------------------ -------------- ------------- -------------
Deferred Tax Liability (1,925) (1,925) -
Other (14,619) - (14,619)
Total Liabilities (16,544) (1,925) (14,619)
------------------------ -------------- ------------- -------------
Retained Earnings 25,141 584 25,725
Other 9,764 - 9,764
Total Equity 34,905 584 35,489
------------------------ -------------- ------------- -------------
Consolidated Income Statement
Impact of correction of error
--------------------------------------------
As previously
For the year ended 31 January 2022 reported Adjustments As restated
GBP'000 GBP'000 GBP'000
Profit before tax 3,963 - 3,963
Income Tax (370) 641 271
Profit for the year 3,593 641 4,234
------------------------------------ -------------- ------------- -------------
Earnings Per Share Impact of correction of error
--------------------------------------------
For the year ended 31 January
2022
As previously
reported Adjustments As restated
Basic EPS 5.28p 0.94p 6.22p
Diluted EPS 5.22p 0.94p 6.16p
Statement of directors' responsibilities
In preparing this preliminary announcement and summary financial statements the directors have considered their statutory responsibilities in relation to the preparation and approval of the annual report and financial statements. In preparing the summary financial statements, the directors have:
-- selected suitable accounting policies and then apply them consistently;
-- stated whether applicable IFRSs as adopted by the European Union have been followed for the Group summary financial statements and United Kingdom Accounting Standards, comprising FRS 101, have been followed for the Company financial statements, subject to any material departures disclosed and explained in the summary financial statements;
-- made judgements and accounting estimates that are reasonable and prudent; and
-- prepared the summary financial statements on the going concern basis unless it is inappropriate to presume that the group and company will continue in business.
In the case of each director in office at the date the summary financial statements are approved:
-- so far as the director is aware, there is no relevant audit information of which the Group and Company's auditors are unaware; and
-- they have taken all the steps that they ought to have taken as a director in order to make themselves aware of any relevant audit information and to establish that the Group and Company's auditors are aware of that information.
Publication of non-statutory accounts
The financial information included in this preliminary announcement does not constitute the Company's statutory accounts for the year ended 31 January 2023 and for the year ended 31 January 2022 but is derived from those accounts. Statutory accounts for the year ended 31 January 2022 have been delivered to the registrar of companies, and those for year ended 31 January 2023 will be delivered in due course. The auditor has reported on those accounts; their reports were (i) unqualified (ii) did not include a reference to any matters to which the auditor drew attention to by way of emphasis without qualifying their report, and (iii) did not contain a statement under section 498 (2) or (3) of the Companies Act 2006. The consolidated financial statements of the Company have been prepared in accordance with international accounting standards in conformity with the requirements of the Companies Act 2006 and in accordance with the UK adopted international accounting standards.
Forward looking statements
Certain statements contained in this document constitute forward-looking statements. Such forward-looking statements involve risks, uncertainties and other factors which may cause the actual results, performance or achievements of Inspiration Healthcare Group plc to be materially different from any future results, performance or achievements expressed or implied by such statements. Such risks, uncertainties and other factors include, among others: general economic conditions and business environment.
Annual Report
A further announcement will be made when the 2023 Annual Report and Financial Statements are available on the Company's website ( www.inspirationhealthcaregroup.plc.uk ) and copies are sent to shareholders.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
FR UUARROVUVRUR
(END) Dow Jones Newswires
May 03, 2023 02:00 ET (06:00 GMT)
1 Year Inspiration Healthcare Chart |
1 Month Inspiration Healthcare Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
